Testing RLY-8161 for advanced cancers with NRAS mutations
Part of Cancer, Skin clinical trials.
This trial tests a new drug called RLY-8161 in people with advanced solid tumors (cancer that has spread) that have a specific genetic mutation called NRAS. The drug is designed to target this mutation and may help slow or shrink tumors that haven't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced cancer (Stage III or IV) that cannot be surgically removed, or melanoma
- Your cancer has an NRAS genetic mutation (confirmed by tumor testing)
- Your cancer has not responded to standard treatments, you couldn't tolerate them, or you chose not to have them
- You have measurable disease on imaging scans (at least one tumor that can be tracked)
- You are in good overall health with minimal limitations (ECOG performance status 0–1)
- You have not previously taken drugs targeting the RAS-MAPK pathway (MEK, ERK, RAF, or RAS inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Hear when a new Advanced NRAS-Mutant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.